Review: Antifungal agents do not reduce mortality in neutropenia caused by chemotherapy or bone marrow transplantation

Rotstein, Coleman
November 2002
ACP Journal Club;Nov/Dec2002, Vol. 137 Issue 3, p98
Academic Journal
Discusses research being done on the influence of antifungal agents on the reduction of mortality in patients with cancer and neutropenia caused by chemotherapy or bone marrow transplantation. Reference to study by H.K. Johansen and colleague; Data soruces; Efficacy of the antifungal agents; Conclusion.


Related Articles

  • A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Oren, I.; Rowe, J. M.; Sprecher, H.; Tamir, A.; Benyamini, N.; Akria, L.; Gorelik, A.; Dally, N.; Zuckerman, T.; Haddad, N.; Fineman, R.; Dann, E. J. // Bone Marrow Transplantation;Jul2006, Vol. 38 Issue 2, p127 

    Fluconazole antifungal prophylaxis is standard care in allogeneic hematopoietic stem cell transplant (HSCT) recipients, but this drug lacks anti-Aspergillus activity, the primary cause of invasive fungal infection (IFI) in many transplantation centers. We performed a randomized trial to compare...

  • Drug regimen cuts rejection.  // USA Today Magazine;Feb94, Vol. 122 Issue 2585, p13 

    Reports on the development of a drug regimen that reduces incidence of major complication of bone marrow transplantation. Limitation of graft versus host disease in recipient; Combination of three drugs; Side-effects of treatment.

  • A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation*. Hartmann, J T; Vangerow, A von; Fels, L M; Knop, S; Stolte, H; Kanz, L; Bokemeyer, C // British Journal of Cancer;2/1/2001, Vol. 84 Issue 3, p313 

    This pilot study evaluates the degree of side effects during high-dose chemotherapy (HD-VIC) plus autologous bone marrow transplant (HDCT) and its possible prevention by the cytoprotective thiol-derivate amifostine. Additionally, the in-patient medical costs of both treatment arms were compared....

  • Additional myeloablation with 52Fe before bone marrow transplantation. Jacquy, C; Ferrant, A; Leners, N; Cogneau, M; Jamar, F; Michaux, J L // Bone Marrow Transplantation;2/1/97, Vol. 19 Issue 3, p191 

    For many hematological malignancies, high-dose chemoradiotherapy followed by bone marrow transplantation offers the best and sometimes the only chance for cure. However, the main causes of failure of this therapy are relapse and toxicity. In order to selectively deliver higher doses of...

  • Autologous bone marrow transplantation in a dog with lymphoma: a clinical study. de Cápua, Maria Luísa Buffo; Dela Coleta, Flávia Eiras; Miotto, Mariana Rodrigues; Calazans, Sabryna Gouveia; Godoy, Aline Vieira; Nakage, Ana Paula Massae; Lisbão, Carolina Bonduki Sales; Daleck, Carlos Roberto; Santana, Aureo Evangelista // Ciência Rural;mar2009, Vol. 39 Issue 2, p580 

    The objective of this study is to provide the first report of bone marrow transplantation (BMT) in dogs in Brazil. A Rottweiler with cutaneous lymphoma was submitted to a twelve-week Madison-Wisconsin chemotherapy protocol followed by autologous bone marrow transplantation. For this, 10mL kg-1...

  • From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML. Krumbholz, M; Bradtke, J; Stachel, D; Peters, O; Hero, B; Holter, W; Slany, R; Metzler, M // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1382 

    The article presents a case study of a 3-year 9-months-old girl who recieved treatment for neuroblastoma and was detected with therapy-related AML (tAML) afterwards. Topics include girl receiving chemotherapy with topotecan, etoposide and cyclophosphamide, detection of progressive neutropenia in...

  • Posaconazole is not superior to itraconazole for fungal prophylaxis in allogeneic blood and marrow transplantation. Mossad, S B // Bone Marrow Transplantation;Oct2012, Vol. 47 Issue 10, p1379 

    A letter to the editor is presented in response to the article "Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation" by I. Saánchez-Ortega and colleagues in the 2012 issue.

  • Reply to SB Mossad. Sánchez-Ortega, I; Encuentra, M; Duarte, R F // Bone Marrow Transplantation;Oct2012, Vol. 47 Issue 10, p1380 

    A response from the author of the article "Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation" in the 2012 issue, which discusses the safety of antifungal prophylaxis, is presented.

  • Granulocyte Colony-Stimulating Factor. Brender, Erin; Glass, Richard M. // JAMA: Journal of the American Medical Association;3/1/2006, Vol. 295 Issue 9, p1088 

    The JAMA patient page discusses granulocyte colony-stimulating factor (G-CSF) and mentions an article published in this journal on March 1, 2006. The article explains how the body naturally produces G-CSF and how it is also available as an injection for patients with low white blood cell counts...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics